Lannett Company Inc (LCI)

0.540
+0.001(+0.09%)
After Hours
0.550
+0.010(+1.758%)
- Real-time Data
  • Volume:
    163,586
  • Day's Range:
    0.540 - 0.565
  • 52 wk Range:
    0.385 - 1.590

LCI Overview

Prev. Close
0.54
Day's Range
0.54-0.565
Revenue
239.95M
Open
0.55
52 wk Range
0.385-1.59
EPS
-5.84
Volume
163,586
Market Cap
22.65M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
176,368
P/E Ratio
-0.09
Beta
0.967
1-Year Change
-62.72%
Shares Outstanding
41,952,489
Next Earnings Date
Feb 01, 2023
What is your sentiment on Lannett?
or
Market is currently closed. Voting is open during market hours.

Lannett Company Inc News

  • Lannett Earnings, Revenue Miss in Q1
    • ByInvesting.com-

    Investing.com - Lannett (NYSE:LCI) reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Lannett announced...

  • Lannett Tops Q2 EPS by 2c
    • ByInvesting.com-

    Lannett (NYSE:LCI) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $74.2 million versus the consensus estimate of...

Lannett Company Inc Analysis

Lannett Company Inc Company Profile

Lannett Company Inc Company Profile

Employees
564

Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.

Read More

Analyst Price Target

Average1.000 (+85.185% Upside)
High1.000
Low1.000
Price0.540
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummarySellStrong SellStrong SellStrong SellStrong Sell
  • No bankrupt … but your price is ugly … back to 3-4$ this year
    0
    • Is this company bankrupt? l taked 7$😞
      0
      • Anyone knows if tomorrow they have a PDUFA for a generic drug? They did not communicate anything but I've red on a calendar about a generic drug for asthma. Anyone knows?
        0
        • this stock is down 49 % since I noticed it - I never really liked it but at this level loaded up quiet a bit at 2.43 $ a share, its worth a roll of the dice, cheers good luck this one is risky
          0
          • what happened here?
            0
            • new nasal spray gives me hopes for LCI
              0
              • What happened here?  Yielded positive results in Diabetes study and *****...down it goes.
                0
                • it's been given pretty good earnings
                  0
                  • PT $3.00 Taking short position on this POS corrupt company.
                    0
                    • its now $13.30 ??? only 3 months after your comments, I think the shorts were listening and covered.....
                      0
                    • new nasal spray gives me hopes for LCI
                      0
                  • Buy
                    0